289 related articles for article (PubMed ID: 21193046)
1. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
[TBL] [Abstract][Full Text] [Related]
2. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Tetreault NA; Mulligan CK; Hutson CB; Masliah E; Chesselet MF
Eur J Neurosci; 2008 Jul; 28(2):247-56. PubMed ID: 18702696
[TBL] [Abstract][Full Text] [Related]
3. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
5. Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α-Synuclein.
Schidlitzki A; Stanojlovic M; Fournier C; Käufer C; Feja M; Gericke B; Garzotti M; Welford RWD; Steiner MA; Angot E; Richter F
Mov Disord; 2023 Jun; 38(6):1044-1055. PubMed ID: 37050861
[TBL] [Abstract][Full Text] [Related]
6. Intranasal Carnosine Mitigates α-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease.
Brown JM; Baker LS; Seroogy KB; Genter MB
ACS Chem Neurosci; 2021 Jul; 12(13):2347-2359. PubMed ID: 34138535
[TBL] [Abstract][Full Text] [Related]
7. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
[TBL] [Abstract][Full Text] [Related]
8. The novel adaptive rotating beam test unmasks sensorimotor impairments in a transgenic mouse model of Parkinson's disease.
Gerstenberger J; Bauer A; Helmschrodt C; Richter A; Richter F
Behav Brain Res; 2016 May; 304():102-10. PubMed ID: 26880341
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Carnosine Intervention in the Thy1-aSyn Mouse Model of Parkinson's Disease.
Bermúdez ML; Seroogy KB; Genter MB
Neuroscience; 2019 Jul; 411():270-278. PubMed ID: 31125602
[TBL] [Abstract][Full Text] [Related]
10. Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.
Magen I; Torres ER; Dinh D; Chung A; Masliah E; Chesselet MF
J Parkinsons Dis; 2015; 5(3):669-680. PubMed ID: 25588356
[TBL] [Abstract][Full Text] [Related]
11. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
12. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression.
Fernagut PO; Hutson CB; Fleming SM; Tetreaut NA; Salcedo J; Masliah E; Chesselet MF
Synapse; 2007 Dec; 61(12):991-1001. PubMed ID: 17879265
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
[TBL] [Abstract][Full Text] [Related]
15. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
16. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.
Tofaris GK; Garcia Reitböck P; Humby T; Lambourne SL; O'Connell M; Ghetti B; Gossage H; Emson PC; Wilkinson LS; Goedert M; Spillantini MG
J Neurosci; 2006 Apr; 26(15):3942-50. PubMed ID: 16611810
[TBL] [Abstract][Full Text] [Related]
17. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
[TBL] [Abstract][Full Text] [Related]
18. Behavioral Deficits and Brain α-Synuclein and Phosphorylated Serine-129 α-Synuclein in Male and Female Mice Overexpressing Human α-Synuclein.
Gabrielyan L; Liang H; Minalyan A; Hatami A; John V; Wang L
J Alzheimers Dis; 2021; 79(2):875-893. PubMed ID: 33361597
[TBL] [Abstract][Full Text] [Related]
19. A GCase chaperone improves motor function in a mouse model of synucleinopathy.
Richter F; Fleming SM; Watson M; Lemesre V; Pellegrino L; Ranes B; Zhu C; Mortazavi F; Mulligan CK; Sioshansi PC; Hean S; De La Rosa K; Khanna R; Flanagan J; Lockhart DJ; Wustman BA; Clark SW; Chesselet MF
Neurotherapeutics; 2014 Oct; 11(4):840-56. PubMed ID: 25037721
[TBL] [Abstract][Full Text] [Related]
20. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]